Reducción persistente de corticosteroides orales independientemente de la dosis basal, en pacientes con asma córtico-dependiente tratados con dupilumab: Estudio Liberty Asthma-Traverse

Translated title of the contribution: Persistent OCS Reduction Regardless of Starting OCS Dose in Patients With Severe, OCSDependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study

Christian Domingo, Mark Gurnell, Klaus F Rabe, Andrew Menzies-Gow, David Price, Guy Brusselle, Michael E Wechsler, Changming Xia, Michel Djandji, Rebecca Gall, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz, Shahid Siddiqui

Research output: Contribution to conferenceAbstractpeer-review

Translated title of the contributionPersistent OCS Reduction Regardless of Starting OCS Dose in Patients With Severe, OCSDependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
Original languageSpanish
Publication statusAccepted/In press - 2 Mar 2022
Event55 Congreso Separ - Pamplona, Spain
Duration: 2 Jun 20224 Jun 2022
Conference number: 55th
https://www.congresosepar.com/SEPAR2022

Conference

Conference55 Congreso Separ
Country/TerritorySpain
CityPamplona
Period2/06/224/06/22
Internet address

Bibliographical note

It will be published in English and Spanish.

Acknowledgments and funding sources
Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Éilis Sutton, PhD, of Excerpta Medica, and was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.

Cite this